Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5979-5987

  Donev, Rossen M ^a   Gray, Lisa C ^a   Sivasankar, Baalasubramanian ^a   Hughes, Timothy R ^a   Van Den Berg, Carmen W ^a   Morgan, B Paul ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; RESTRICTIVE SILENCER FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; COMPLEMENT; PEPTIDE; RE1 SILENCING TRANSCRIPTION FACTOR; RE1-SILENCING TRANSCRIPTION FACTOR; REPRESSOR PROTEIN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BRAIN TUMOR; CELL NUCLEUS; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, CD59; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL NUCLEUS; COMPLEMENT SYSTEM PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOTHERAPY; NEUROBLASTOMA; PEPTIDES; REPRESSOR PROTEINS; RNA INTERFERENCE;

EID: 48649083030     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6828     Document Type: Article

References (46)

1. Walport MJ. Advances in immunology: complement (first of two parts). N Engl J Med 2001;344:1058-66.
2. Magyarlaki T, Mosolits S, Baranyay F, Buzogany I. Immunohistochemistry of complement response on human renal cell carcinoma biopsies. Tumori 1996;82:473-9.
3. Lucas SD, KarlssonParra A, Nilsson B, et al.. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 1996;27:1329-35.
4. Matsumoto M, Takeda J, Inoue N, et al. A novel protein that participates in nonself discrimination of malignant cells by homologous complement. Nat Med 1997;3:1266-70.
5. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complement- regulatory proteins in ovarian malignancies. Int J Cancer 1997;70:14-25.
6. Rushmere NK, Knowlden JM, Gee JMW, et al. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. Int J Cancer 2004;108:930-6.
7. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 1999;20:576-82.
8. Maloney DG, Smith B, Rose A. Rituximab: Mechanism of action and resistance. Semin Oncol 2002;29:2-9.
9. Imai M, Landen C, Ohta R, Cheung NKV, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res 2005;65:10562-8.
10. Takei K, Yamazaki T, Sawada U, Ishizuka H, Aizawa S. Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. Leukemia Res 2006;30:625-31.
11. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
12. Macor P, Tripodo C, Zorzet S, et al. In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. Cancer Res 2007;67:10556-63.
13. Eggert US, Field CM, Mitchison TJ. Small molecules in an RNAi world. Mol Biosys 2006;2:93-6.
14. Donev RM, Cole DS, Sivasankar B, Hughes TR, Morgan BP. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Res 2006;66:2451-8.
15. Chong JHA, Tapiaramirez J, Kim S, et al. REST - a mammalian silencer protein that restricts sodium-channel gene expression to neurons. Cell 1995;80:949-57.
16. Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF) - a coordinate repressor of multiple neuron-specific genes. Science 1995;267:1360-3.
17. Westbrook TF, Martin ES, Schlabach MR, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005;121:837-48.
18. Palm K, Metsis M, Timmusk T. Neuron-specific splicing of zinc finger transcription factor REST/NRSF/XBR is frequent in neuroblastomas and conserved in human, mouse and rat. Mol Brain Res 1999;72:30-9.
19. Coulson JM, Edgson JL, Woll PJ, Quinn JP. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res 2000;60:1840-4.
20. Donev R, Horton R, Beck S, et al. Recruitment of heterogeneous nuclear ribonucleoprotein A1 in vivo to the LMP/TAP region of the major histocompatibility complex. J Biol Chem 2003;278:5214-26.
21. Enukashvily N, Donev R, Sheer D, Podgornaya O. Satellite DNA binding and cellular localisation of RNA helicase P68. J Cell Sci 2005;118:611-22.
22. Kim CS, Hwang CK, Choi HS, et al. Neuron-restrictive silencer factor (NRSF) functions as a repressor in neuronal cells to regulate the mu opioid receptor gene. J Biol Chem 2004;279:46464-73.
23. Orlando V, Paro R. Mapping polycomb-repressed domains in the bithorax complex using in vivo formaldehyde cross-linked chromatin. Cell 1993;75:1187-98.
24. Coulson JM, Stanley J, Woll PJ. Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer. Br J Cancer 1999;80:1935-44.
25. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside-GD2 on human neuroblastoma cells - target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47:1098-104.
26. Holguin MH, Martin CB, Eggett T, Parker CJ. Analysis of the gene that encodes the complement regulatory protein, membrane inhibitor of reactive lysis (CD59) - Identification of an alternatively spliced exon and characterization of the transcriptional regulatory regions of the promoter. J Immunol 1996;157:1659-68.
27. Coulson JM. Transcriptional regulation: Cancer, neurons and the REST. Curr Biol 2005;15:R665-8.
28. Majumder S. REST in good times and bad - roles in tumor suppressor and oncogenic activities. Cell Cycle 2006;5:1929-35.
29. Baalasubramanian S, Harris CL, DonevRM, et al. CD59a is the primary regulator of membrane attack complex assembly in the mouse. J Immunol 2004;173:3684-92.
30. Donev RM, Sivasankar B, Mizuno M, Morgan BP. The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility. Mol Immunol 2008;45:534-42.
31. Shimojo M, Lee JH, Hersh LB. Role of zinc finger domains of the transcription factor neuron-restrictive silencer factor/repressor element-1 silencing transcription factor in DNA binding and nuclear localization. J Biol Chem 2001;276:13121-6.
32. Nadler SG, Tritschler D, Haffar OK, Blake J, Bruce AG, Cleaveland JS. Differential expression and sequence-specific interaction of karyopherin a with nuclear localization sequences. J Biol Chem 1997;272:4310-5.
33. Protopopova M, Selivanova G. Inhibition of p53 activity in vitro and in living cells by a synthetic peptide derived from its core domain. Cell Cycle 2003;2:592-5.
34. Bodian DL, Davis SJ, Morgan BP, Rushmere NK. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med 1997;185:507-16.
35. van Beek J, van Meurs M, t Hart BA, et al. Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol 2005;174:2353-65.
36. Kimberley FC, Sivasankar B, Morgan BP. Alternative roles for CD59. Mol Immunol 2007;44:73-81.
37. Chen SH, Caragine T, Cheung NKV, Tomlinson S. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 2000;60:3013-8.
38. Kimura Y, Furuhata T, Urano T, Hirata K, Nakamura Y, Tokino T. Genomic structure and chromosomal localization of GML (GPI-anchored molecule-like protein), a gene induced by p53. Genomics 1997;41:477-80.
39. Gazouli M, Kokotas S, Zoumpourlis V, et al. The complement inhibitor CD59 and the lymphocyte function-associated antigen-3 (LFA-3, CD58) genes possess functional binding sites for the p53 tumor suppressor protein. Anticancer Res 2002;22:4237-41.
40. Plaisance V, Niederhauser G, Azzouz F, et al. The repressor element silencing transcription factor (REST)-mediated transcriptional repression requires the inhibition of Sp1. J Biol Chem 2005;280:401-7.
41. Shimojo M, Hersh LB. REST/NRSF-interacting LIM domain protein, a putative nuclear translocation receptor. Mol Cell Biol 2003;23:9025-31.
42. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 2004;4:106-17.
43. Davies CS, Harris CL, Morgan BP. Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects. Immunol 2005;114:280-6.
44. Spix C, Aareleid T, Stiller C, Magnani C, Kaatsch P, Michaelis J. Survival of children with neuroblastoma: time trends and regional differences in Europe, 1978-1992. Eur J Cancer 2001;37:722-9.
45. Johnson E, Dean S, Sondel P. Antibody-based immunotherapy in high-risk neuroblastoma. Expert Rev Mol Med 2007;9:1-21.
46. Imai M, Ohta R, Varela J, Song H, Tomlinson S. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res 2007;67:9535-41.